Synergistic improvements to polynucleotide vaccines
CA 2405424 A1 · Owner: Takabayashi, Kenji · Inventors: Takabayashi, Kenji; Raz, Eyal; Nguyen, Minh-Duc
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention features a polynucleotide vaccine modified to enhance expression of the encoded antigen in host cells. The polynucleotide vaccine comprises an antigen-encoding nucleic acid sequence derived from a non-host species of a first phylum or first kingdom, wherein the native signal sequence of the antigen coding sequence is deleted and optionally, replaced with a signal , sequence of a polypeptide of a second phylum or a second kingdom that is functional in the host to be immunized (e.g. a viral signal sequence with a plant antigen-encoding sequence). In one embodiment the signal sequence is a , hemagglutinin A (HA) signal sequence and the antigen is an allergen (e.g. plant …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 6, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 6, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 6, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.